Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) ...

U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital will participate ...

If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for ...

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced multiple clinical research results to be presented at the 2025 American Society of Clinical ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As traditional research institutions ...

A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

The irony is glaring," said Boise. "The DEA blocks lawful drug development while cartels profit. The agency is both gatekeeper and roadblock-and now, a constitutional liability." The DEA's own 2025 ...

Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby the following resolutions were made. Adoption of the income statement ...